相似文献
1
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
Cancer Cell. 2009 Jun 2;15(6):501-13. doi: 10.1016/j.ccr.2009.03.018.
2
CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.
Neuro Oncol. 2013 Jul;15(7):865-79. doi: 10.1093/neuonc/not029. Epub 2013 May 3.
3
The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor.
Int J Biochem Cell Biol. 2014 Apr;49:8-16. doi: 10.1016/j.biocel.2014.01.007. Epub 2014 Jan 13.
4
Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors.
Lab Invest. 2011 Jul;91(7):1068-78. doi: 10.1038/labinvest.2011.56. Epub 2011 Apr 11.
5
Long non-coding RNA lung cancer-associated transcript-1 promotes glioblastoma progression by enhancing Hypoxia-inducible factor 1 alpha activity.
Neuro Oncol. 2024 Aug 5;26(8):1388-1401. doi: 10.1093/neuonc/noae036.
6
Acidic stress promotes a glioma stem cell phenotype.
Cell Death Differ. 2011 May;18(5):829-40. doi: 10.1038/cdd.2010.150. Epub 2010 Dec 3.
7
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.
Cell Cycle. 2009 Oct 15;8(20):3274-84. doi: 10.4161/cc.8.20.9701. Epub 2009 Oct 3.
8
The U2AF2 /circRNA ARF1/miR-342-3p/ISL2 feedback loop regulates angiogenesis in glioma stem cells.
J Exp Clin Cancer Res. 2020 Sep 7;39(1):182. doi: 10.1186/s13046-020-01691-y.
9
The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
Cell Death Differ. 2015 Sep;22(9):1517-25. doi: 10.1038/cdd.2015.7. Epub 2015 Feb 27.
10
Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EphA2.
Theranostics. 2024 Sep 9;14(15):5778-5792. doi: 10.7150/thno.95141. eCollection 2024.
引用本文的文献
1
Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.
Biomedicines. 2025 Aug 12;13(8):1963. doi: 10.3390/biomedicines13081963.
2
Cancer stem cells: landscape, challenges and emerging therapeutic innovations.
Signal Transduct Target Ther. 2025 Aug 5;10(1):248. doi: 10.1038/s41392-025-02360-2.
3
From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research.
Nat Methods. 2025 Jul 25. doi: 10.1038/s41592-025-02769-1.
4
New approaches to overcome radioresistance in glioblastoma: mechanisms, targets and role of innovative therapies, new particles and non-photon radiotherapy in 2024. A systematic review.
Rep Pract Oncol Radiother. 2025 Jun 7;30(2):269-281. doi: 10.5603/rpor.105654. eCollection 2025.
5
HIF-1α and HIF-2α: synergistic regulation of glioblastoma malignant progression during hypoxia and apparent chemosensitization in response to hyperbaric oxygen.
Cancer Cell Int. 2025 Jul 3;25(1):251. doi: 10.1186/s12935-025-03823-w.
6
Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.
Front Pharmacol. 2025 Apr 11;16:1575332. doi: 10.3389/fphar.2025.1575332. eCollection 2025.
7
Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance.
Cells. 2025 Apr 9;14(8):562. doi: 10.3390/cells14080562.
8
Natural bioactive gallic acid shows potential anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells.
Mol Med Rep. 2025 Jun;31(6). doi: 10.3892/mmr.2025.13516. Epub 2025 Apr 11.
9
Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade.
Cell Mol Life Sci. 2025 Mar 17;82(1):119. doi: 10.1007/s00018-025-05642-8.
10
A conditionally replicative adenovirus vector containing the synNotch receptor gene for the treatment of muscle-invasive bladder cancer.
Cancer Gene Ther. 2025 Mar;32(3):306-317. doi: 10.1038/s41417-025-00879-8. Epub 2025 Feb 26.
本文引用的文献
1
Efficient tumour formation by single human melanoma cells.
Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.
2
White fat progenitor cells reside in the adipose vasculature.
Science. 2008 Oct 24;322(5901):583-6. doi: 10.1126/science.1156232. Epub 2008 Sep 18.
3
Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis.
Cancer Res. 2008 Aug 15;68(16):6533-40. doi: 10.1158/0008-5472.CAN-07-6642.
4
Targeting cancer stem cells through L1CAM suppresses glioma growth.
Cancer Res. 2008 Aug 1;68(15):6043-8. doi: 10.1158/0008-5472.CAN-08-1079.
5
CD133 identifies perivascular niches in grade II-IV astrocytomas.
J Neurooncol. 2008 Nov;90(2):157-70. doi: 10.1007/s11060-008-9648-8. Epub 2008 Jul 9.
6
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29.
7
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.
Cell Stem Cell. 2007 Oct 11;1(4):389-402. doi: 10.1016/j.stem.2007.08.001.
8
Uncertainty in the niches that maintain haematopoietic stem cells.
Nat Rev Immunol. 2008 Apr;8(4):290-301. doi: 10.1038/nri2279. Epub 2008 Mar 7.
9
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
J Clin Oncol. 2008 Jan 10;26(2):271-8. doi: 10.1200/JCO.2007.13.3652.
10
Influence of oxygen tension on CD133 phenotype in human glioma cell cultures.
Cancer Lett. 2007 Dec 18;258(2):286-90. doi: 10.1016/j.canlet.2007.09.012. Epub 2007 Oct 30.
Zotero 插件